Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: Results of a multicentre phase 2 clinical trial

Owen A. O'Connor, Craig Moskowitz, Carol Portlock, Paul Hamlin, David Straus, Otilia Dumitrescu, Debra Sarasohn, Mithat Gonen, John Butos, Ellen Neylon, Rachel Hamelers, Barbara Mac-Gregor Cortelli, Susan Blumel, Andrew D. Zelenetz, Leo Gordon, John J. Wright, Julie Vose, Brenda Cooper, Jane Winter

Research output: Contribution to journalArticlepeer-review

64 Scopus citations

Fingerprint

Dive into the research topics of 'Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: Results of a multicentre phase 2 clinical trial'. Together they form a unique fingerprint.

Medicine & Life Sciences